BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects

Author(s): Md Atiqur Rahman, Ali Salajegheh, Robert Anthony Smith, Alfred King-yin Lam

Journal Name: Current Cancer Drug Targets

Volume 14 , Issue 2 , 2014

Become EABM
Become Reviewer
Call for Editor


BRAF is a major oncoprotein and oncogenic mutations in BRAF are found in a significant number of cancers, including melanoma, thyroid cancer, colorectal cancer and others. Consequently, BRAF inhibitors have been developed as treatment options for cancers with BRAF mutations which have shown some success in improving patient outcomes in clinical trials. Development of resistance to BRAF kinase inhibitors is common, however, overcoming this resistance is an area of significant concern for clinicians, patients and researchers alike. In this review, we identify the mechanisms of BRAF kinase inhibitor resistance and discuss the implications for strategies to overcome this resistance in the context of new approaches such as multi-kinase targeted therapies and emerging RNA interference based technologies.

Keywords: BRAF, BRAF, gene therapy, kinase inhibitors, treatment resistance.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 21 January, 2014
Page: [128 - 143]
Pages: 16
DOI: 10.2174/1568009614666140121150930
Price: $65

Article Metrics

PDF: 54